Precision Optics (POCI) Q3 2026: Gross Margin Jumps to 24% as Manufacturing Scale Drives Inflection
Precision Optics delivered a record quarter, with operational gains translating into a 24% gross margin and positive adjusted EBITDA for the first time. The company’s core aerospace and single-use medical device programs both hit new highs, while improved yields and disciplined cost control unlocked financial leverage. With a strengthened balance sheet and multiple new production ramps slated for fiscal 2027, POCI is positioned for accelerated, margin-accretive growth as it transitions from engineering-led to scaled manufacturing leadership.
Summary
- Operational Leverage Emerges: Margin expansion and positive adjusted EBITDA reflect structural improvements in manufacturing and cost discipline.
- Pipeline Ramps in Focus: Multiple programs set to enter production underpin confidence in sustained top-line and margin growth.
- Facility and Platform Investments: Capital deployment targets micro-optics leadership and accelerated product cycles via the Unity platform.
Business Overview
Precision Optics designs and manufactures advanced optical components and systems, primarily for the medical device, aerospace and defense, and satellite communications markets. The company generates revenue through production contracts for complex micro-optics assemblies and endoscopic systems, as well as engineering services for custom product development. Its major segments include high-volume production for single-use medical devices, aerospace assemblies for satellite applications, and specialty optics via its Ross Optical division. POCI’s business model is anchored in scaling proprietary manufacturing processes to meet growing demand for smaller, higher-performance optical solutions across its end markets.
Performance Analysis
This quarter marked a clear operational inflection for Precision Optics, as revenue more than doubled year-over-year and gross margin expanded sharply to 24% from 10% a year ago. The company’s two largest production programs—the aerospace assembly and single-use cystoscope—delivered record revenue, with the aerospace line up 44% sequentially and cystoscope up 10%. Critically, production yields improved to 97% on the aerospace line and above 90% on cystoscope, directly supporting margin gains and operational stability.
Ross Optical, the specialty optics division, contributed $1.3 million in revenue, up 65% year-over-year, and was highlighted as a high-margin contributor due to its low incremental cost structure. Cost discipline was evident, with SG&A down year-over-year despite higher consulting and bonus expenses, and R&D focused on pipeline enablement. The company achieved positive adjusted EBITDA of $300,000, a milestone that underscores the scalability of its manufacturing improvements and sets a new baseline for financial performance.
- Yield Improvement Drives Margin: Consistent 97% yields on the aerospace line and rising yields on cystoscope meaningfully reduced scrap and rework costs.
- Ross Optical Delivers Variable Margin: Incremental revenue from Ross Optical flows efficiently to gross profit, supporting EBITDA leverage.
- Tariff Management Mitigates Volatility: Agreements to pass through tariffs without markup and anticipated refundable credits reduce risk and support future margins.
With a $10 million capital raise completed and cash at $10.7 million, POCI is well-funded to support upcoming production ramps and facility upgrades. The company’s updated guidance reflects confidence in sustaining this operational momentum.
Executive Commentary
"More importantly, we achieved positive adjusted EBITDA, a major milestone that reflects both the strength of our core production programs and the manufacturing improvements we've made over the last several quarters."
Dr. Joe Forkey, Chief Executive Officer
"This was a major milestone for the company and reflects the combination of record revenue, improved manufacturing performance, better yield, and continued operating expense discipline."
Wayne Cole, Chief Financial Officer
Strategic Positioning
1. Manufacturing Scale and Operational Discipline
POCI’s transformation from an engineering-centric to a scaled manufacturing organization is now visible in its financials. The hiring of a new COO last year catalyzed process overhauls, team restructuring, and a culture of urgent, data-driven execution. Yield and throughput improvements are translating to higher margins and reduced operating leverage risk.
2. Diversified Growth Engines
While the aerospace and cystoscope programs anchor near-term results, POCI is actively ramping additional verticals. The Ross Optical division’s growth is both sustainable and margin-accretive, while the pipeline includes single-use ophthalmic endoscopes and a suite of new device launches slated for fiscal 2027. This diversification reduces dependence on any one program and supports multi-year growth visibility.
3. Platform Leverage via Unity
The Unity platform, a modular imaging architecture, is designed to accelerate product development and reduce time-to-market for both reusable and single-use endoscopes. Although adoption has lagged initial expectations, recent traction with four new sales prospects suggests Unity may become a key lever for pipeline velocity and customer stickiness, with each program targeted at $1–3 million in annualized production revenue.
4. Targeted Capital Allocation
Recent capital raises are earmarked for facility modernization, quality and supply chain infrastructure, and targeted go-to-market expansion in high-growth end markets. Management is evaluating options to consolidate and upgrade its Gardner, MA manufacturing footprint to support future volume, with a focus on minimizing disruption while enhancing scalability and compliance.
5. Market Alignment and Customer Partnerships
POCI’s focus on miniaturization and single-use devices aligns with secular trends in medical and defense markets. Strategic customer partnerships—such as co-located production lines and royalty-bearing licensing arrangements—deepen integration and create recurring revenue streams, while also mitigating competitive risk.
Key Considerations
The quarter’s results mark a strategic turning point but also highlight several areas for continued vigilance as POCI scales.
Key Considerations:
- Aerospace Program Volatility: Customer-requested production slowdown in Q1–Q2 2027 due to downstream bottlenecks could pressure near-term revenue, though management expects a rebound and offset from new ramps.
- Pipeline Execution Risk: Transitioning five to six new programs from development to production in fiscal 2027 introduces complexity and potential for yield or timeline slippage.
- Facility Upgrade Timing: Decisions on facility consolidation or modernization must balance growth capacity with operational continuity and cost discipline.
- Unity Platform Adoption: While the Unity platform shortens R&D-to-production cycles, broader adoption and sales messaging remain a work in progress.
- Tariff and Supply Chain Dynamics: Tariff pass-throughs and potential credits are net positives, but ongoing geopolitical risk and customer inventory strategies could introduce quarter-to-quarter variability.
Risks
Key risks include execution on multiple concurrent production ramps, customer concentration in core programs, and macro uncertainty in end markets such as aerospace and medical devices. Facility upgrade decisions and supply chain disruptions could impact cost structure or delay new product launches. The sustainability of margin gains hinges on continued yield improvements and operational rigor as volumes grow. Tariff and regulatory changes remain a background risk, though current agreements mitigate near-term impact.
Forward Outlook
For Q4 2026, POCI guided to:
- Continued strong performance in core aerospace and cystoscope programs, with aerospace expected to see a 15–20% pullback in Q1–Q2 2027 before rebounding.
- Ramp-up of new production lines, including single-use ophthalmic endoscopes and additional devices entering production within six months.
For full-year 2026, management raised guidance:
- Revenue of $29–31 million (previously $26–28 million)
- Adjusted EBITDA of negative $2.5 to negative $2.7 million (improved from prior range)
Management emphasized confidence in margin improvement, pipeline conversion, and the sustainability of Ross Optical’s revenue base as key drivers for the remainder of the year and into fiscal 2027.
- Facility upgrades and operational investments to support long-term volume growth
- Unity platform traction and new customer onboarding as incremental upside levers
Takeaways
POCI’s Q3 results validate its operational transformation and set the stage for scalable, profitable growth.
- Manufacturing Execution: Margin expansion and positive EBITDA confirm that yield and throughput improvements are sustainable and leverageable.
- Pipeline Visibility: Multiple new production ramps and Unity-driven programs support multi-year growth, but execution on transitions will be critical.
- Capital and Facility Strategy: Disciplined capital deployment and facility upgrades are necessary to support rising volume and complexity without margin erosion.
Conclusion
Precision Optics enters the final quarter of fiscal 2026 with clear operational momentum, a strengthened balance sheet, and a robust pipeline of new production programs. The company’s evolution into a scaled, margin-accretive manufacturer is now evident in its results, but continued vigilance on execution, facility strategy, and new program ramps will determine the durability of its inflection.
Industry Read-Through
POCI’s margin inflection and production ramp signal broader demand for miniaturized, high-performance optical systems in medical, aerospace, and communications markets. The focus on single-use medical devices and modular imaging platforms mirrors secular trends toward disposability and rapid innovation cycles in medtech. Aerospace and satellite customers’ need for supply chain resilience and high-yield manufacturing is increasingly a differentiator, with POCI’s experience suggesting that operational excellence can unlock both margin and customer stickiness. For optics and photonics peers, the quarter underscores the importance of vertical integration, flexible capacity, and platform-based development to capture share in high-growth, high-mix markets.